Provided by Tiger Fintech (Singapore) Pte. Ltd.

Beam Therapeutics, Inc.

19.13
+0.89004.88%
Post-market: 19.820.6900+3.61%19:59 EDT
Volume:1.98M
Turnover:37.56M
Market Cap:1.92B
PE:-4.18
High:19.31
Open:18.38
Low:18.34
Close:18.24
Loading ...

Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Zacks
·
21 Feb

CRSP Stock Rises 25% in a Week: Time to Buy, Hold or Sell?

Zacks
·
18 Feb

Is Beam Therapeutics (BEAM) Outperforming Other Medical Stocks This Year?

Zacks
·
10 Feb

Beam Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co.

Dow Jones
·
03 Feb

Beam Therapeutics Inc.'s (NASDAQ:BEAM) Prospects Need A Boost To Lift Shares

Simply Wall St.
·
31 Jan

Investors in Beam Therapeutics (NASDAQ:BEAM) from three years ago are still down 55%, even after 3.8% gain this past week

Simply Wall St.
·
31 Jan

Beam Therapeutics Raised to Overweight From Neutral by Cantor Fitzgerald

Dow Jones
·
29 Jan

Cantor Fitzgerald Upgrades Beam Therapeutics to Overweight From Neutral

MT Newswires Live
·
29 Jan

Wall Street Analysts Think Beam Therapeutics (BEAM) Could Surge 84.45%: Read This Before Placing a Bet

Zacks
·
28 Jan

Is it a Good Idea to Invest in Beam Therapeutics Stock Now?

Zacks
·
24 Jan

Positive Report for Beam Therapeutics (BEAM) from Bernstein

TIPRANKS
·
24 Jan

Has Alzamend Neuro (ALZN) Outpaced Other Medical Stocks This Year?

Zacks
·
23 Jan

Beam Therapeutics to encore data from BEACON Phase 1/2 trial of Beam-101

TIPRANKS
·
23 Jan

BRIEF-Beam Therapeutics To Encore Data From Beacon Phase 1/2 Clinical Trial Of Beam-101

Reuters
·
23 Jan

Beam Therapeutics to Encore Data From Beacon Phase 1/2 Clinical Trial of Beam-101 in Sickle Cell Disease at 2025 Tandem Meetings of Astct and Cibmtr

THOMSON REUTERS
·
23 Jan

Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR

GlobeNewswire
·
23 Jan

CRISPR Therapeutics Stock Falls 34% in a Year: Time to Buy or Sell?

Zacks
·
17 Jan

Bernstein Keeps Their Buy Rating on Beam Therapeutics (BEAM)

TIPRANKS
·
14 Jan

Is Beam Therapeutics (BEAM) Stock a Solid Choice Right Now?

Zacks
·
13 Jan

BRIEF-Beam Therapeutics Announces Progress In Hematology And Genetic Disease Franchises

Reuters
·
13 Jan